Kymera Therapeutics (KYMR) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
2 Nov, 2026Executive summary
KT-579 Phase 1 showed ≥90% median IRF5 degradation across multiple-dose cohorts, broad biomarker modulation across immune pathways and placebo-comparable safety.
KT-621 is in Phase 2b trials for atopic dermatitis and asthma; KT-579’s LUMORA lupus Phase 1b study is planned for early 2027.
Financial highlights
Q3 collaboration revenue was $0, versus $2.764M in Q3 2025; no additional collaboration revenue is expected in 2026.
Q3 R&D expense was $128.509M versus $74.094M; G&A was $18.7M versus $17.3M.
Q3 net loss was $131.999M versus $82.175M; diluted loss per share was $1.32 versus $0.94.
Nine-month collaboration revenue was $99.365M versus $36.341M; net loss was $262.444M versus $224.370M.
Q3 adjusted cash R&D was $117.6M, up 8% QoQ; adjusted cash G&A was $10.8M, down 14% QoQ.
Outlook and guidance
KT-621 BROADEN2 atopic dermatitis results are expected by year-end 2026; the first AD Phase 3 trial is targeted for mid-2027, subject to supportive results and FDA alignment.
KT-621 BREADTH asthma Phase 2b results are expected in late 2027; KT-579 LUMORA lupus trial start is planned by early 2027.
KT-200 IND filing is targeted for 2027; Gilead is conducting IND-enabling studies.
Cash and securities of $1,645.883M at September 30, 2026 are expected to fund operations into 2029; R&D and G&A are expected to rise as development advances.
Latest events from Kymera Therapeutics
- Early clinical data support oral STAT6 and IRF5 degraders, with key trials ahead.KYMR
Company presentation - Accelerated KT-621 development and broad type 2 disease expansion signal strong pipeline momentum.KYMR
Stifel 2026 Virtual Immunology and Inflammation Forum - Accelerated clinical progress in oral immunology therapies sets stage for broad expansion.KYMR
Wells Fargo 21st Annual Healthcare Conference - KT-621's clinical progress positions it to transform oral therapy options in atopic dermatitis.KYMR
Morgan Stanley 24th Annual Global Healthcare Conference - STAT6 program advances with phase IIb data expected by year-end, supporting phase III plans.KYMR
H.C. Wainwright 28th Annual Global Investment Conference - Oral immunology therapies targeting STAT6 and IRF5 advance toward key data readouts this year.KYMR
Citigroup’s Biopharma Back to School Summit 2026 - Oral degraders advance as transformative therapies for immunology and oncology, targeting major unmet needs.KYMR
Corporate presentation - KT-621 and KT-579 progress rapidly; $65M Q2 revenue, $61.2M net loss, $1.5B cash runway.KYMR
Q2 2026 - KT-621 achieved >90% STAT6 degradation, strong Th2 biomarker reduction, and excellent safety.KYMR
Study Result